Search

In this article, we consider the following fractional (p , q) -Laplacian problem (− Δ) p s 1 u + (− Δ) q s 2 u + V (x) (| u | p − 2 u + | u | q − 2 u) = f (u) + λ | u | r − 2 u , where x ∈ R N , (− Δ) p s 1 is the fractional p-Laplacian operator ( (− Δ) q s 2 is similar), 0 < s 1 < s 2 < 1 < p < q < N s 2 , q s 2 * = N q N − s 2 q , r ≥ q s 2 * , f is a C 1 real function and V is a coercive function. By using variational methods, we prove that the above problem admits a sign-changing solution if λ > 0 is small. [ABSTRACT FROM AUTHOR]

AbstractThe continuous integration and refinement of electronic equipment results in the more stringent requirements for epoxy resin (EP) based materials, such as excellent heat dissipation and low coefficient of thermal expansion (CTE). In order to improve the dispersion of silica powder (SP) in EP and thus expand the application of EP in the field of electronic packaging, our research described in this paper adopted the KH-550 coupling agent to modify the surface of SP (m-SP). The effects of KH-550 coupling agent on the characteristics of the composites were investigated in terms of thermal, rheological, electrical insulation and mechanical properties. The results showed that when the content of KH-550 was 2 wt% of the fillers, the best modification effect was achieved, and the surface properties of the fillers were changed accordingly. In particular, the materials filled with m-SP exhibited lower viscosity end, better mechanical and electrical insulation properties. It was also found that the adding of the KH-550 had different effects on the thermal degradation, dynamic thermo-mechanical properties and the thermal deformation behavior of the materials. According to our study, the thermal conductivity and the CTE of m-SP/EP filled with 70 wt% of modified fillers were 0.787 W/m.K and 28.3 ppm/°C respectively, corresponding to a significant thermal conductivity improvement and low CTE. [ABSTRACT FROM AUTHOR]

Aims: Treatment resistance commonly emerges in small cell lung cancer (SCLC), necessitating the development of novel and effective biomarkers to dynamically assess therapeutic efficacy. This study aims to evaluate the clinical utility of aneuploid circulating tumor cells (CTCs) for risk stratification and treatment response monitoring., Methods: A total of 126 SCLC patients (two cohorts) from two independent cancer centers were recruited as the study subjects. Blood samples were collected from these patients and aneuploid CTCs were detected. Aneuploid CTC count (ACC) and aneuploid CTC score (ACS), were used to predict progression-free survival (PFS) and overall survival (OS). The performance of the ACC and the ACS was evaluated by calculating the area under the receiver operating characteristic (ROC) curve (AUC)., Results: Compared to ACC, ACS exhibited superior predictive power for PFS and OS in these 126 patients. Moreover, both univariate and multivariate analyses revealed that ACS was an independent prognostic factor. Dynamic ACS changes reflected treatment response, which is more precise than ACC changes. ACS can be used to assess chemotherapy resistance and is more sensitive than radiological examination (with a median lead time of 2.8 months; P < 0.001). When patients had high ACS levels (> 1.115) at baseline, the combination of immunotherapy and chemotherapy resulted in longer PFS (median PFS, 7.7 months; P = 0.007) and OS (median OS, 16.3 months; P = 0.033) than chemotherapy alone (median PFS, 4.9 months; median OS, 13.6 months)., Conclusions: ACS could be used as a biomarker for risk stratification, treatment response monitoring, and individualized therapeutic intervention in SCLC patients., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)